Evolution of the polypill concept and ongoing clinical trials

Canadian Journal of Cardiology

Volumn 30, Issue 5, 2014, Pages 520-526

  Castellano, Jose M ^a   Sanz, Gines ^b   Fuster, Valentin ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; VACCINATION;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; WORLD HEALTH;

EID: 84899643894     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.02.016     Document Type: Review

References (37)

1. Ezzati M., Hoorn S.V., Rodgers A., et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003, 362:271-280.
2. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet 2012, 380:2095-2128.
3. Yusuf S., Islam S., Chow C.K., et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 2011, 378:1231-1243.
4. Nieuwlaat R., Schwalm J.D., Khatib R., Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease?. Eur Heart J 2013, 34:1262-1269.
5. Chapman R.H., Benner J.S., Petrilla A.A., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165:1147-1152.
6. Sanz G., Fuster V. Polypill and global cardiovascular health strategies. Semin Thorac Cardiovasc Surg 2011, 23:24-29.
7. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002, 360:2-3.
8. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
9. Sleight P., Pouleur H., Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 2006, 27:1651-1656.
10. Sanz G., Fuster V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. Mt Sinai J Med 2012, 79:683-688.
11. Lonn E., Yusuf S. Polypill: the evidence and the promise. Curr Opin Lipidol 2009, 20:453-459.
12. Wald D.S., Wald N.J. The polypill in the primary prevention of cardiovascular disease. Fund Clin Pharmacol 2010, 24:29-35.
13. Wald D.S., Morris J.K., Wald N.J. Randomized polypill crossover trial in people aged 50 and over. PLoS One 2012, 7:e41297.
14. Xavier D., Pais P., Sigamani A., et al. The need to test the theories behind the polypill: rationale behind the Indian Polycap Study. Nat Clin Pract Cardiovasc Med 2009, 6:96-97.
15. Malekzadeh F., Marshall T., Pourshams A., et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypil') on cardiovascular risk factors. Int J Clin Pract 2010, 64:1220-1227.
16. Soliman E.Z., Mendis S., Dissanayake W.P., et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011, 12:3.
17. Group P.C., Rodgers A., Patel A., et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One 2011, 6:e19857.
18. Thom S., Poulter N., Field J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013, 310:918-929.
19. The International Polycap Study 3 (TIPS-3). Available at: Accessed November 15th, 2013. http://clinicaltrials.gov/show/NCT01646437.
20. Heart Outcomes Prevention Evaluation-3. Available at: Accessed November 15th, 2013. http://clinicaltrials.gov/show/NCT00468923.
21. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill. Available at: Accessed November 15th, 2013. http://clinicaltrials.gov/ct2/show/NCT01271985.
22. Law M.G. Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention-the HIV polypill study. Curr Opin HIV AIDS 2006, 1:482-487.
23. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713-719.
24. Pan F., Chernew M.E., Fendrick A.M. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Int Med 2008, 23:611-614.
25. Dickson M., Plauschinat C.A. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008, 8:45-50.
26. Sanz G., Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009, 6:101-110.
27. Fuster V., Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action. Nat Clin Pract Cardiovasc Med 2007, 4:173.
28. Thom S., Field J., Poulter N., et al. Use of a multidrug pill in reducing cardiovascular events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2014, 21:252-261.
29. Sanz G., Fuster V., Guzman L., et al. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J 2011, 162:811-817.e1.
30. Narayan K.M., Mensah G.A., Sorensen S., et al. Combination pharmacotherapy for cardiovascular disease prevention: threat or opportunity for public health?. Am J Prev Med 2005, 29:134-138.
31. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
32. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
33. Dagenais G.R., Pogue J., Fox K., Simoons M.L., Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006, 368:581-588.
34. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27:335-371.
35. Muntner P., Mann D., Wildman R.P., et al. Projected impact of polypill use among us adults: medication use, cardiovascular risk reduction, and side effects. Am Heart J 2011, 161:719-725.
36. Gaziano T.A., Opie L.H., Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006, 368:679-686.
37. Lim S.S., Gaziano T.A., Gakidou E., et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370:2054-2062.